Biomarker Use in Colorectal Cancer Therapy

被引：29

作者：

Kelley, Robin K. ^{[1
]}

Wang, Grace ^{[2
]}

Venook, Alan P.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA 94115 USA

[2] UCSF, Ctr Translat & Policy Res Personalized Med, San Francisco, CA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2011年 / 9卷 / 11期

关键词：

Colon cancer; colorectal cancer; biomarker; KRAS; BRAF; microsatellite instability; mismatch repair; REVISED BETHESDA GUIDELINES; DEFECTIVE MISMATCH REPAIR; CIRCULATING TUMOR-CELLS; MICROSATELLITE-INSTABILITY; ADJUVANT CHEMOTHERAPY; COLON-CANCER; LYNCH-SYNDROME; PREDICTIVE BIOMARKERS; MOLECULAR PREDICTORS; THYMIDYLATE SYNTHASE;

D O I：

10.6004/jnccn.2011.0105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biomarkers reflective of the molecular and genetic heterogeneity in colorectal cancers now guide certain aspects of clinical management and offer great potential for enrichment, stratification, and identification of novel therapeutic targets in drug development. Using case-based examples, this article reviews biomarkers that have an established role in the clinical management of colorectal cancer: mismatch repair protein testing and KRAS and BRAF mutational analysis. A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed. (JNCCN 2011;9:1293-1303)

引用

页码：1293 / 1302

页数：10

共 50 条

[41] Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
Tie, Jeanne
Desai, Jayesh
TARGETED ONCOLOGY, 2015, 10 (02) : 179 - 188
[42] Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, Gerhard
Hernandez-Illan, Eva
Moreira, Leticia
Balaguer, Francesc
Goel, Ajay
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (02) : 111 - 130
[43] Pharmacogenomic-Guided Therapy in Colorectal Cancer
Diasio, Robert B.
Innocenti, Federico
Offer, Steven M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 616 - 625
[44] Biomarkers and stage II colorectal cancer therapy
Zijoo, Ritika
Olszanski, Anthony J.
Weinberg, David S.
TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S84 - S86
[45] Guanylyl cyclase C as a biomarker in colorectal cancer
Hyslop, Terry
Waldman, Scott A.
BIOMARKERS IN MEDICINE, 2013, 7 (01) : 159 - 167
[46] Molecular biology of colorectal cancer in clinical practice
Kit, O. I.
Vodolazhsky, D. I.
MOLECULAR BIOLOGY, 2015, 49 (04) : 471 - 479
[47] Pathologic Predictors of Microsatellite Instability in Colorectal Cancer
Greenson, Joel K.
Huang, Shu-Chen
Herron, Casey
Moreno, Victor
Bonner, Joseph D.
Tomsho, Lynn P.
Ben-Izhak, Ofer
Cohen, Hector I.
Trougoubhoff, Phillip
Bejhar, Jacob
Sova, Yanina
Pinchev, Mila
Rennert, Gad
Gruber, Stephen B.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (01) : 126 - 133
[48] Microsatellite Instability and Therapeutic Consequences in Colorectal Cancer
Laghi, Luigi
Malesci, Alberto
DIGESTIVE DISEASES, 2012, 30 (03) : 304 - 309
[49] Current trends in clinical genetics of colorectal cancer
Markovic, Srdjan
Dimitrijevic, Ivan
Zogovic, Branimir
Markovic, Velimir
Barisic, Goran
Krivokapic, Zoran
JOURNAL OF BUON, 2016, 21 (05): : 1042 - 1049
[50] The role of tumour markers and biomarkers in colorectal cancer
Lech, G.
Slotwinski, R.
Krasnodebski, I. W.
NEOPLASMA, 2014, 61 (01) : 1 - 8

← 1 2 3 4 5 →